BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BioCentury | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...
BioCentury | Apr 15, 2019
Distillery Therapeutics

Inhibiting NOX2 or FOXC1 to treat AML and CML

...Acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML) Cell culture and mouse studies suggest inhibiting NOX2...
...could include identifying and testing inhibitors of NOX2 and FOXC1 in the models. TARGET/MARKER/PATHWAY: NADPH oxidase 2 (NOX2...
...T. Jordan, University of Colorado, Aurora, Colo. email: craig.jordan@ucdenver.edu Claire Quang University of Colorado Forkhead box C1 (FOXC1) NADPH oxidase 2 (NOX2) Chronic...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Nov 9, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BioCentury | Nov 5, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples from patients with squamous cell carcinoma of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or...
BioCentury | Aug 8, 2017
Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

In a paper published in the Journal of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of these...
Items per page:
1 - 10 of 221